A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination with Bendamustine (+ Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients with Advanced Non-Hodgkin Lymphoma After at Least 1 Prior Line of Therapy

Type of Cancer
Lymphoma

Sponsor
Millennium Pharmaceuticals Inc.

Protocol Number
C34005

To Learn More Call
201-510-0910